Have you or someone you know been diagnosed with myelodysplastic syndromes (MDS)?
Announcing a new clinical research trial.
Learn more about P02978
The MDS Foundation wants you to know about clinical trials of investigational treatment options for patients with MDS. In the current clinical research trials, all patients will receive therapy with Lonafarnib, an investigational drug that is being evaluated for treating patients with MDS or CMML who have been regularly receiving at least 1 and not more than 8 platelet transfusions every 4 weeks. The medicine is taken by mouth at home, and although patients will be monitored closely, routine hospital stays are not required.
About the MDS Foundation: The MDS Foundation is a publicly supported, multidisciplinary, international organization devoted to the prevention, treatment, and study of MDS. The Foundation has conducted international symposia and has established an international information network that provides patients with referrals to the MDS Foundation's Centers of Excellence worldwide, contact names for available programs, and information about new research and treatment options. The Foundation also provides educational support to both physicians and patients.
For more information about clinical trials with Lonafarnib, call the MDS Foundation at 1-888-813-1260 (outside the US 609-298-7741)
Talk to your doctor to decide if this trial is suitable for you.
Schering-Plough is the sponsor of this trial. This ad was supported by a grant from Schering-Plough.
Clinical Trial Announcement for Platelet Transfusion-Dependent Patients with MDS or CMML
